However, it is difficult to interpret if the association with an increased risk of a decrease in LVEF and arterial hypertension under the BRAF and MEK combination presented here is a MEK-mediated adverse event or if this is subsequent to a more efficient inhibition of the MAPK pathway through dual therapy. This evidence concerns the gene BRAF and Hypertension.